Feb 10, 2025 | Cost Savings, Drug costs, Pharmacogenomics, Rx Costs, Savings
Now available through MedBen Rx, pharmacogenomic testing is transforming health care through safer and more effective personalized medicine. Determining how genes affect a person’s response to drugs not only improves patient outcomes, but it also helps control...
Oct 15, 2024 | Benefits preservation, Biosimilar, Claims, Cost Savings, Drug costs, Rx Costs, Savings, Specialty Drugs
Specialty drugs continue to drive up pharmacy costs, accounting for over 50% of total drug spend for many self-funded health plans, despite being used by a small percentage of patients. But pharmaceutical and administrative solutions are available to help reduce that...
Aug 5, 2024 | Biosimilar, Cost Savings, Food and Drug Administration (FDA), Humalog, Opinions, Savings
From a STAT opinion piece by Juliana M. Reed, executive director of the Biosimilars Forum: “Biologic medicines are some of the most important drugs in the world. They are also among the most expensive. Biosimilars are FDA-approved treatments that are similar to...
Jul 5, 2024 | Biosimilar, Cost Savings, Drug costs, Humira, Idacio, MedBen Rx, News, Rx Costs, Savings
The Food and Drug Administration is considering a change to its biosimilar policy that would greatly speed up their approval process – which, if enacted, would be a big win for MedBen Rx clients who are already reducing their prescription drug spend through...
Apr 16, 2024 | Biosimilar, Cost Savings, Drug costs, Humira, Idacio, Prescription drugs, Rx Costs, Savings
Last year, MedBen Rx announced a new program that would enable clients to purchase Idacio, a biosimilar version of the anti-inflammatory therapy Humira – a drug that typically costs between $6,000 and $12,000 per month depending on the dose – for under $1,000 per...
Apr 1, 2024 | Benefits preservation, Comparative Effectiveness, Cost Savings, Drug costs, MedBen Rx, Pharmacies, Pharmacy Benefits Manager (PBM), Rx Costs, Savings, Specialty Drugs, Transparency
Employers are turning away from the “big three” pharmacy benefits managers to other PBMs that offer greater transparency and lower costs, says Wharton professor of health care management Lawton Robert Burns. As one of those alternatives, MedBen Rx is...
